Vilobelimab
Vilobelimab Uses, Dosage, Side Effects, Food Interaction and all others data.
Vilobelimab is under investigation in clinical trial NCT03895801 (Study of IFX-1 to Replace Steroids in Patients With Granulomatosis With Polyangiitis and Microscopic Polyangiitis).
| Trade Name | Vilobelimab |
| Generic | Vilobelimab |
| Vilobelimab Other Names | IFX-1, Vilobelimab |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
How Vilobelimab works
Vilobelimab is an inhibitor targeting C5a in human plasma which helps markedly alleviate systemic inflammatory responses, and is being investigated in patients with acute lung injury. This neutralizing antihuman antibody acts by blocking the activation of C5a and thereby inhibits granulocyte expression of CD11b.
Innovators Monograph
You find simplified version here Vilobelimab
